BIONTECH SE SPON. ADRS 1
Commented by Stefan Feulner on April 12th, 2022 | 20:31 CEST
BioNTech, Desert Gold Ventures, BYD - Decisive steps
There is currently great uncertainty on the capital markets. While the Ukraine war and the fear of interest rate hikes due to the enormous increase in inflation are weighing on the minds of investors in Europe, investors in Asia are pulling back due to the tightened Corona measures in China. The zero-covid policy could result in widespread mass shutdowns, negatively impacting industrial production and domestic consumption. Electric car maker NIO, for example, has already halted production.
Read
Commented by Stefan Feulner on April 9th, 2022 | 07:27 CEST
BioNTech, Triumph Gold, Rheinmetall - Uncertainties everywhere
The ongoing fighting in Ukraine and concerns about an escalation of the situation are worrying capital markets worldwide. Nevertheless, the leading stock market barometers were able to distance themselves significantly from their lows. Now, the next blow has followed with the publication of the FED's meeting minutes. The US Federal Reserve wants to accelerate the reduction of its balance sheet total and let bonds worth up to USD 95 billion expire without buying again. In doing so, the monetary authorities are hitting technology stocks in particular, which have already been in a sharp correction since the beginning of the year. Gold, on the other hand, is barely reacting despite the expected interest rate hikes, a strong sign for the precious metal.
Read
Commented by Nico Popp on April 4th, 2022 | 11:20 CEST
Millions with innovations: BioNTech, Meta Materials, Varta
When the long-forgotten solar company SolarWorld went public in 1999, n-tv ran commercials that, from today's perspective, looked rather amateurish. At that time, too, only a few private investors were initially convinced by the Company. Years later, SolarWorld was a success story - investors from the very beginning had become rich. Even though the Company filed for insolvency in the meantime and burned a lot of money - SolarWorld investors of the first hour are mostly still wealthy. We explain where innovations can develop blockbuster potential.
Read
Commented by André Will-Laudien on April 1st, 2022 | 12:43 CEST
BioNTech, Defence Therapeutics, Valneva, CureVac - Stocks with blockbuster potential!
With the Ukraine crisis, international vaccination activity has taken a back seat. The world's northern hemisphere is gearing up for next summer, so flu diseases are also slowly taking a back seat. However, the COVID virus will likely continue to mutate over the summer and will reappear in a new guise in the fall. Germany's maximum vaccination rate of 76% has been reached, with just under a quarter of the population ultimately foregoing vaccination after lengthy public measures. For the major biotech companies, it is now a case of - The country needs new products! There are still many areas of application in the field of mRNA. Which stocks stand out with their pipeline?
Read
Commented by Juliane Zielonka on March 29th, 2022 | 13:34 CEST
Valneva, Triumph Gold, BioNTech - Gold rush mood in the pipeline
While the Corona measures are eased in Spain, and the government lets symptom-free positive tested persons out of quarantine, Germany tightens again and extends the measures. This could create a gold-rush mood among BioNTech investors, as figures from the Mainz-based biotech Company will be announced on Wednesday. Valneva is also looking ahead with confidence to the first shipment of its liquid gold in the form of the COVID-19 inactivated vaccine. For investors with a more earthy disposition, it is a good idea to look at the real precious metals and gold deposits these days. For example, an investment in Canada's Triumph Gold Corporation offers copper and diamond deposits in addition to gold. The Company specializes in the discovery and development of gold and other valuable commodity deposits.
Read
Commented by Nico Popp on March 22nd, 2022 | 11:22 CET
In the right place at the right time: BioNTech, Defence Therapeutics, Bayer
For years, the pandemic has kept the world on tenterhooks. Currently, the epidemic is taking a break, at least in the media. But while the world is looking tautly at Ukraine and more and more refugees are arriving in Germany, the Omicron figures are rising once more. In some cases, the incidence in Germany is over 3,000. Although fewer and fewer people are dying, more people than ever are in quarantine. We look at BioNTech, a typical pandemic stock, and present other exciting investments from the healthcare sector.
Read
Commented by Carsten Mainitz on March 14th, 2022 | 12:47 CET
BioNTech, Defence Therapeutics, MorphoSys - Shares with blockbuster potential!
Developing a blockbuster drug is the highest achievement in the pharmaceutical industry. A blockbuster is defined as a drug that can generate more than USD 1 billion in revenues per year. According to experts, the vaccine Comirnaty, developed by BioNTech and Pfizer, is likely to have brought in sales of well over USD 30 billion, thus clearly breaking the blockbuster barrier. Outside of vaccine research, there are also numerous companies with high long-term potential.
Read
Commented by Juliane Zielonka on March 3rd, 2022 | 13:12 CET
Cardiol, BioNTech, Novartis - Inventory at three high-flyers
Good news, this time from Cardiol Therapeutics. Both the US FDA and regulatory authorities in Brazil and Mexico have given the green light for the inclusion of patients already vaccinated against COVID-19 in the LANCER trial. The opening with respect to this patient group increases the likelihood of a speedy trial completion. The pandemic cannot be over until global efforts are made to fight the virus together. So BioNTech will build a plant in Rwanda. And Novartis, as an experienced Big Pharma giant, illustrates through its quarterly figures how valuable the pharmaceutical industry as a whole can be as an investment.
Read
Commented by Armin Schulz on March 2nd, 2022 | 11:24 CET
BioNTech, XPhyto Therapeutics, Valneva - Where are the Corona winners?
Even if the Corona coverage, which has prevailed for 2 years, has recently been replaced by the Ukraine conflict, the pandemic is not yet over. RKI chief Wieler recently reported increased outbreaks in nursing homes and rising incidences among the elderly. Health Minister Lauterbach also sees the wave not yet broken and reports the highest death rates in months. Since the legal basis for the Corona measures expires on March 19, a new law has been introduced to allow measures to be enacted beyond that date. Which companies could benefit?
Read
Commented by Stefan Feulner on February 24th, 2022 | 10:23 CET
Lufthansa, mm2 Asia, BioNTech - Clear the way for the rebound
After the strong increase by the Omicron variant, the infection numbers are decreasing, and the world is breathing a sigh of relief. Due to the high vaccination rates, politicians are loosening existing restrictions. It is hard to believe, going to cinemas, restaurants and even discos is allowed again. Bookings for the travel season are increasing daily, and flying, provided you don't want to go to Kiev or Odesa at the moment, is possible at any time. Due to the almost two-year standstill, there are interesting opportunities to participate in the revived business, especially in the entertainment industry.
Read